Literature DB >> 23641421

Building better biotherapeutics and vaccines by design: EpiVax, Inc., an immunology company.

Leonard Moise1, Annie De Groot, Anthony Marcello, Ryan Tassone, William Martin, Leslie Cousens.   

Abstract

EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.

Entities:  

Keywords:  autoimmune diseases; immuno- therapy; immunoinformatics; immunomodulation; vaccines

Mesh:

Substances:

Year:  2013        PMID: 23641421

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN: 0363-7913


  3 in total

Review 1.  Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.

Authors:  Mathieu Dondelinger; Patrice Filée; Eric Sauvage; Birgit Quinting; Serge Muyldermans; Moreno Galleni; Marylène S Vandevenne
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

2.  Computational mining of MHC class II epitopes for the development of universal immunogenic proteins.

Authors:  Kyle Saylor; Ben Donnan; Chenming Zhang
Journal:  PLoS One       Date:  2022-03-29       Impact factor: 3.240

Review 3.  The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.

Authors:  Lea Skak Filtenborg Frederiksen; Yibang Zhang; Camilla Foged; Aneesh Thakur
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.